Economic Notes: opportunity cost.
作者信息
Palmer S, Raftery J
机构信息
Centre for Health Economics, University of York, York YO1 5DD.
出版信息
BMJ. 1999 Jun 5;318(7197):1551-2. doi: 10.1136/bmj.318.7197.1551.
Abstract
摘要
相似文献
1
Economic Notes: opportunity cost.
BMJ. 1999 Jun 5;318(7197):1551-2. doi: 10.1136/bmj.318.7197.1551.
2
When Opportunity Knocks, What Does It Say?
Value Health. 2019 Aug;22(8):851-853. doi: 10.1016/j.jval.2019.05.008. Epub 2019 Jul 27.
3
Prognosis without treatment as a modifier in health economic assessments.
BMJ. 2005 Jun 11;330(7504):1382-4. doi: 10.1136/bmj.330.7504.1382.
4
Theory and methods of economic evaluation of health care.
Dev Health Econ Public Policy. 1996;4:1-245.
5
Economics, QALYs and medical ethics: a practical agenda?
Health Care Anal. 1995 Aug;3(3):229-32. doi: 10.1007/BF02197673.
6
The DH register of cost-effectiveness studies: content and quality.
Health Trends. 1995;27(2):50-6.
7
Economics, QALYs and medical ethics--a health economist's perspective.
Health Care Anal. 1995 Aug;3(3):221-6. doi: 10.1007/BF02197671.
8
Review of NICE's recommendations, 1999-2005.
BMJ. 2006 May 27;332(7552):1266-8. doi: 10.1136/bmj.332.7552.1266.
9
Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence.
N Engl J Med. 2008 Nov 6;359(19):1977-81. doi: 10.1056/NEJMp0806862.
10
How much are Americans willing to pay for a quality-adjusted life year?
Med Care. 2008 Apr;46(4):343-5. doi: 10.1097/MLR.0b013e31816a7144.
引用本文的文献
1
Exploratory analysis of the economically justifiable price of reslizumab for asthma severe in Colombia.
BMC Public Health. 2025 Jun 6;25(1):2116. doi: 10.1186/s12889-025-23205-1.
2
Quantifying societal burden of radiation-induced small bowel toxicity in patients with rectal cancer.
Front Oncol. 2024 Jul 8;14:1340081. doi: 10.3389/fonc.2024.1340081. eCollection 2024.
3
Twentieth-Century Change in the Educational Costs of Adolescent Childbearing.
AJS. 2024 May;129(6):1763-1791. doi: 10.1086/729819.
4
Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature.
Pharmacoeconomics. 2024 Jul;42(7):737-749. doi: 10.1007/s40273-024-01377-9. Epub 2024 Apr 27.
5
Reporting time toxicity in prospective cancer clinical trials: A scoping review.
Support Care Cancer. 2024 Apr 8;32(5):275. doi: 10.1007/s00520-024-08487-2.
6
The underuse of AI in the health sector: Opportunity costs, success stories, risks and recommendations.
Health Technol (Berl). 2024;14(1):1-14. doi: 10.1007/s12553-023-00806-7. Epub 2023 Dec 12.
7
Global HIV Incidence Analysis and Implications for Affordability Using Long-Acting Cabotegravir Versus Continuous and Event-Driven Oral Preexposure Prophylaxis.
Clin Infect Dis. 2024 Feb 17;78(2):386-394. doi: 10.1093/cid/ciad537.
8
Screening for primary prevention of fragility fractures: How much time does it take?
Can Fam Physician. 2023 Aug;69(8):537-541. doi: 10.46747/cfp.6908537.
9
Offering No-Cost Cosmetic Revisions: The Experience of an Academic Cosmetic Surgery Program.
Aesthet Surg J Open Forum. 2023 Mar 29;5:ojad033. doi: 10.1093/asjof/ojad033. eCollection 2023.
10
No such thing as a free lunch: The direct marginal costs of breastfeeding.
J Perinatol. 2023 May;43(5):678-682. doi: 10.1038/s41372-023-01646-z. Epub 2023 Mar 22.
本文引用的文献
1
A practical guide for calculating indirect costs of disease.
Pharmacoeconomics. 1996 Nov;10(5):460-6. doi: 10.2165/00019053-199610050-00003.
2
Perspectives in economic evaluation.
BMJ. 1998 May 16;316(7143):1529-30. doi: 10.1136/bmj.316.7143.1529.
3
Indirect cost in economic evaluation: the opportunity cost of unpaid inputs.
Health Econ. 1996 Jan-Feb;5(1):13-23. doi: 10.1002/(SICI)1099-1050(199601)5:1<13::AID-HEC182>3.0.CO;2-J.
4
Marginal costs and benefits.
BMJ. 1996 Jan 6;312(7022):35-6. doi: 10.1136/bmj.312.7022.35.
5
Costs and cost-minimisation analysis.
BMJ. 1993 Sep 18;307(6906):726-8. doi: 10.1136/bmj.307.6906.726.
6
Opportunity costs in modern medicine.
Health Aff (Millwood). 1992 Summer;11(2):162-9. doi: 10.1377/hlthaff.11.2.162.
Zotero 插件